Saphire Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.11 M
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.50 M
- Revenue Growth 26.97%
- Profit Growth 16.71%
- Ebitda -4.40%
- Net Worth 16.36%
- Total Assets -1.40%
About Saphire Biotech
Saphire Biotech Private Limited (SBPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 November 2004 and has a history of 20 years and three months. Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹5.50 M.
Hemant Kulkarni, Mihir Kulkarni, and Ketki Kulkarni serve as directors at the Company.
Company Details
-
Location
Bhopal, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24246MP2004PTC017081
-
Company No.
017081
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Nov 2004
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Saphire Biotech?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mihir Kulkarni
|
Director | 30-Mar-2019 | Current |
|
Hemant Kulkarni
|
Director | 21-Jun-2005 | Current |
|
Ketki Kulkarni
|
Director | 07-Jan-2013 | Current |
Financial Performance of Saphire Biotech.
Saphire Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 26.97% increase. The company also saw a substantial improvement in profitability, with a 16.71% increase in profit. The company's net worth Soared by an impressive increase of 16.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saphire Biotech?
In 2022, Saphire Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.55 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Feb 2022 | Others | ₹0.50 M | Open |
| 31 Oct 2019 | Others | ₹5.00 M | Open |
How Many Employees Work at Saphire Biotech?
Saphire Biotech has a workforce of 9 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saphire Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saphire Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
